MedPath

The Effects of Sildenafil on Exercise Function and Capacity in Patients With Fontan Circulation

Phase 4
Completed
Conditions
Fontan Circulation
Interventions
Drug: Placebo
Drug: Placebo 2
Registration Number
NCT00964782
Lead Sponsor
Milton S. Hershey Medical Center
Brief Summary

The study will test the hypothesis that a single dose of sildenafil can increase the exercise capacity of pediatric patients with a Fontan Circulation.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
17
Inclusion Criteria
  • Age 6-17 years
  • Male or female
  • Possess Fontan Circulation
Exclusion Criteria
  • Severe heart failure (New York Heart Ass. functional class IV)
  • Evidence of Fontan pathway obstruction
  • History of exercise-induced severe arrhythmias
  • Pregnancy (known or suspected)
  • Orthopedic limitations that prevent ambulation on a treadmill
  • Use of nitroglycerin
  • Herbal medications

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Sildenafil crossover to placeboSildenafilSildenafil dosage (0.5mg/kg (max 20mg)) administered at the time of enrollment followed by a battery of exercise tests. After a washout period, the process will be repeated with treatment 2, placebo drug administered before the exercises.
Sildenafil crossover to placeboPlacebo 2Sildenafil dosage (0.5mg/kg (max 20mg)) administered at the time of enrollment followed by a battery of exercise tests. After a washout period, the process will be repeated with treatment 2, placebo drug administered before the exercises.
Placebo crossover to sidenafilPlaceboPatient will receive a look-alike placebo administered at the time of enrollment followed by a battery of exercise tests. After a washout period, the process will be repeated with treatment 2 Sildenafil dosage will be 0.5mg/kg (max 20mg) administered before the exercises.
Placebo crossover to sidenafilSildenafil 2Patient will receive a look-alike placebo administered at the time of enrollment followed by a battery of exercise tests. After a washout period, the process will be repeated with treatment 2 Sildenafil dosage will be 0.5mg/kg (max 20mg) administered before the exercises.
Primary Outcome Measures
NameTimeMethod
The Change in Exercise Capacity Measured Via Exercise Timebaseline to 1 hour

A change in exercise capacity measured via exercise time (in minutes). The measurement will be obtained from the Exercise Stress Test

The Change in Exercise Capacity Measured Via Maximum Oxygen Consumed During Exercise (VO2)baseline to 1 hour

A change in exercise capacity measured via maximum oxygen consumed during exercise (VO2). The measurement will be obtained from the Exercise Stress Test

Secondary Outcome Measures
NameTimeMethod
The Change in Exercise Capacity Measured Via Maximum Heart RateBaseline to 1 Hour

A change in exercise capacity measured via maximum heart rate (in beats per minute). The measurement will be obtained from the Exercise Stress Test

The Change in Exercise Capacity Measured Via Minimum Oxygen Saturation Levels.Baseline to 1 Hour

A change in exercise capacity measured via minimum oxygen saturation (%). The measurement will be obtained from the Exercise Stress Test

The Change in Exercise Capacity Measured Via Metabolic Equivalents of Task (METs).Baseline to 1 hour

A change in exercise capacity measured via metabolic equivalents of task (METs). The measurement will be obtained from the Exercise Stress Test. One MET is defined as 3.5 mL 02 uptake/kg per minute

Trial Locations

Locations (1)

Penn State Hershey Medical Center

🇺🇸

Hershey, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath